ZNTL241220C5000
- 0.20
- 0.000.00%
Zentalis Pharmaceuticals Newsroom
Express News | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guggenheim Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Cuts Target Price to $8
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $20
Express News | Zentalis Pharmaceuticals Inc : Guggenheim Cuts Target Price to $8 From $12
Express News | HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $20 Price Target
Zentalis Pharma Analyst Ratings
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $9
Cautious Hold on Zentalis Pharmaceuticals Amid Strategic Shifts and Safety Concerns
Zentalis Pharmaceuticals: Strong Leadership and Promising Clinical Developments Justify Buy Rating
Zentalis Pharmaceuticals Announces Julie Eastland Appointed Chief Executive Officer, President And Director; Scott Myers Appointed To The Board Of Directors As Chairperson
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals: Kimberly Blackwell to Remain as Strategic Advisor to the Bd >ZNTL
Zentalis Pharmaceuticals Scott Myers Appointed to the Bd of Directors as Chairperson >ZNTL
Press Release: Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
Express News | Zentalis Pharmaceuticals Inc - Julie Eastland Appointed CEO, President and Director
Express News | Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
Zentalis Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Zentalis Pharmaceuticals Insiders Still US$137k Away From Original Investment Value
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings